

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Goulmy et al.

Serial No.: 09/489,760

Filed: January 21, 2000

For: THE HA-1 ANTIGEN

Confirmation No.: 6225

Examiner: P. Huynh

Group Art Unit: 1644

Attorney Docket No.: 2183-4285US

VIA HAND DELIVERY

STATEMENT UNDER 37 C.F.R. §§ 1.821 THROUGH 1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Andrew F. Nilles, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:


1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), are included herewith to comply with the requirements of 37 C.F.R. §§ 1.821 and/or 1.825 as requested by the Examiner.

2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be the same as the paper copy of the substitute SEQUENCE LISTING.

Serial No.: 09/489,760

3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Andrew F. Nilles', with a stylized flourish at the end.

Andrew F. Nilles
Registration No. 47,825
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 27, 2003

AFN/bv

Document in ProLaw

SEQUENCE LISTING

<110> Goulmy, Elsa A.J.M
 Hunt, Donald F
 Engelhard, Victor H

<120> The HA-1 Antigen

<130> 2183-4285US

<140> 09/489,760

<141> 2000-01-21

<150> PCT/NL98/00424

<151> 1998-07-23

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Histocompatibility antigen

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa is HISTIDINE OR ARGININE RESIDUE

<400> 1

Val Leu Xaa Asp Asp Leu Leu Glu Ala

1 5

<210> 2

<211> 9

<212> PRT

<213> Histocompatibility antigen

<400> 2

Val Leu His Asp Asp Leu Leu Glu Ala

1 5

<210> 3

<211> 9

<212> PRT

<213> Histocompatibility antigen

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is ISOLEUCINE OR LEUCINE

<400> 3

Tyr Xaa Thr Asp Arg Val Met Thr Val
1 5

<210> 4

<211> 9

<212> PRT

<213> Histocompatibility antigen

<220>

<221> MISC_FEATURE

<222> (2)..(7)

<223> Xaa is LEUCINE OR ISOLEUCINE

<400> 4

Val Xaa His Asp Asp Xaa Xaa Glu Ala
1 5

<210> 5

<211> 9

<212> PRT

<213> KIAA0223 partial complementary DNA

<400> 5

Val Leu Arg Asp Asp Leu Leu Glu Ala
1 5

<210> 6

<211> 25

<212> DNA

<213> Unknown

<220>

<223> Reverse primer

<400> 6

gctcctgcat gacgctctgt ctgca

25

<210> 7

<211> 24

<212> DNA

<213> Unknown

<220>

<223> Forward primer

<400> 7

gacgtcgtcg aggacatctc ccat

24

<210> 8
 <211> 25
 <212> DNA
 <213> Unknown

 <220>
 <223> Reverse Primer

 <400> 8
 gaaggccaca gcaatcgtct ccagg 25

 <210> 9
 <211> 30
 <212> DNA
 <213> Unknown

 <220>
 <223> HA-1" allele primer H1

 <400> 9
 ccttgagaaa cttaaggagt gtgtgctgca 30

 <210> 10
 <211> 30
 <212> DNA
 <213> Unknown

 <220>
 <223> HA-1r allele primer R1

 <400> 10
 ccttgagaaa cttaaggagt gtgtgttgcg 30

 <210> 11
 <211> 33
 <212> DNA
 <213> Forward KIAA00223 based PCR primer

 <400> 11
 ccggcatgga cgtcgtcgag gacatctccc atc 33

 <210> 12
 <211> 30
 <212> DNA
 <213> Reverse KIAA00223 based PCR primer

 <400> 12
 ctacttcagg ccacagcaat cgtctccagg 30

<210> 13
<211> 38
<212> DNA
<213> Unknown

<220>
<223> HA-1-/-

<400> 13
gagtggtgtgt tgcgtgacga cctccttgag gcccgccg

38

<210> 14
<211> 13
<212> PRT
<213> Unknown

<220>
<223> HA-1-/-

<400> 14
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg
1 5 10

<210> 15
<211> 38
<212> DNA
<213> Unknown

<220>
<223> HA-1+/+

<400> 15
gagtggtgtgc tgcattgacga cctccttgag gcccgccg

38

<210> 16
<211> 13
<212> PRT
<213> Unknown

<220>
<223> HA-1+/+

<400> 16
Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg
1 5 10

<210> 17
<211> 10

<212> PRT

<213> Unknown

<220>

<223> Peptide that can bind recombinant HLA-A2.1 and b2microglobulin

<400> 17

Phe Leu Pro Ser Asp Cys Phe Pro Ser Val

1 5 10